EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect

Whi-An Kwon iD, Jae Young Joung

Cancers · 21.03.2025 · 17 (7) · 1064

DOI: 10.3390/cancers17071064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.03.2025. Verfasst von Whi-An Kwon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has shown limited efficacy in prostate cancer, largely due to low tumor immunogenicity, sparse tumor-infiltrating lymphocytes, and a suppressive microenvironment. Recent therapeutic strategies aim to boost immune responses and counteract immunosuppressive factors through interventions such as immune checkpoint inhibitors, immunogenic cell death-inducing therapies, and the targeted blockade of pathways like that of transforming growth factor-β. Vaccine-based approaches, potent immune adjuvants, and engineered chimeric antigen receptor (CAR) T cells are also being investigated to overcome local immune inhibitory signals. Advancements in imaging, multi-omic profiling, and liquid biopsies offer promising avenues for real-time monitoring, better patient selection, and precision treatment. This review provides an overview of the key immunosuppressive features of prostate cancer, current immunotherapeutic modalities, and emerging strategies to transform “cold” tumors into more responsive “hot” targets. By integrating these approaches, we may achieve more durable clinical benefits for patients with advanced or metastatic prostate cancer.

Schlagwörter

Stichwörter der Autor:innen

androgen receptorcancer vaccinesimmune checkpoint inhibitorsimmunosuppressive microenvironmentimmunotherapymicrosatellite instabilityprostate cancertumor microenvironment

Autor:innen und Institutionen

  • Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.
  • Department of Urology, Urological Cancer Center, National Cancer Center, Goyang 10408, Republic of Korea.

ORCID-Profile: Whi-An Kwon

Förderung

  • National Cancer Center

Zitieren

APA

Kwon, W. A., & Joung, J. Y. (2025). Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect. Cancers, 17(7), 1064. https://doi.org/10.3390/cancers17071064

Vancouver

Kwon WA, Joung JY. Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect. Cancers. 2025;17(7):1064. doi:10.3390/cancers17071064

BibTeX
@article{Kwon2025,
  author = {Kwon, Whi-An and Joung, Jae Young},
  title = {Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {1064},
  doi = {10.3390/cancers17071064}
}
Kostenlos starten →